Tetraphase Pharmaceuticals Stock Price, News & Analysis (NASDAQ:TTPH)

$6.88 0.50 (7.84 %)
(As of 11/20/2017 04:28 AM ET)
Previous Close$6.38
Today's Range$6.29 - $6.96
52-Week Range$3.57 - $9.93
Volume575,000 shs
Average Volume723,365 shs
Market Capitalization$353.73 million
P/E RatioN/A
Dividend YieldN/A
Beta2.52

About Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Tetraphase Pharmaceuticals logoTetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:TTPH
  • CUSIP: N/A
  • Web: www.tphase.com
Debt:
  • Current Ratio: 7.55%
  • Quick Ratio: 7.55%
Sales & Book Value:
  • Annual Sales: $5.14 million
  • Price / Sales: 68.83
  • Book Value: $3.79 per share
  • Price / Book: 1.82
Profitability:
  • Trailing EPS: ($2.87)
  • Net Income: ($77,480,000.00)
  • Net Margins: -1,382.33%
  • Return on Equity: -88.27%
  • Return on Assets: -77.53%
Misc:
  • Employees: 66
  • Outstanding Shares: 51,420,000
 

Frequently Asked Questions for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

What is Tetraphase Pharmaceuticals' stock symbol?

Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."

How were Tetraphase Pharmaceuticals' earnings last quarter?

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) announced its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.63). The biopharmaceutical company earned $4.10 million during the quarter, compared to analysts' expectations of $1.59 million. Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The firm's quarterly revenue was up 355.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.58) earnings per share. View Tetraphase Pharmaceuticals' Earnings History.

Where is Tetraphase Pharmaceuticals' stock going? Where will Tetraphase Pharmaceuticals' stock price be in 2017?

5 brokerages have issued twelve-month price targets for Tetraphase Pharmaceuticals' shares. Their predictions range from $13.00 to $24.00. On average, they anticipate Tetraphase Pharmaceuticals' stock price to reach $17.00 in the next twelve months. View Analyst Ratings for Tetraphase Pharmaceuticals.

Who are some of Tetraphase Pharmaceuticals' key competitors?

Who are Tetraphase Pharmaceuticals' key executives?

Tetraphase Pharmaceuticals' management team includes the folowing people:

  • Leonard Patrick Gage Ph.D., Chairman of the Board of Directors (Age 74)
  • Guy Macdonald, President and Chief Executive Officer, Director (Age 56)
  • Christopher Watt, Principal Financial Officer, Principal Accounting Officer, Senior Vice President - Finance (Age 51)
  • Kamalam Unninayar, Chief Financial Officer
  • Maria D. Stahl, Senior Vice President, General Counsel (Age 44)
  • Patrick T. Horn M.D. Ph.D., Chief Medical Officer (Age 60)
  • Jeffrey A. Chodakewitz M.D., Director (Age 61)
  • Geraldine A. Henwood Ph.D., Director (Age 61)
  • Garen G. Bohlin, Independent Director (Age 69)
  • John G. Freund M.D., Independent Director (Age 63)

Who owns Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Canada Pension Plan Investment Board (5.00%), Dimensional Fund Advisors LP (2.84%), JPMorgan Chase & Co. (2.33%), Candriam Luxembourg S.C.A. (0.76%), Bank of New York Mellon Corp (0.46%) and Schwab Charles Investment Management Inc. (0.42%). Company insiders that own Tetraphase Pharmaceuticals stock include Jacques Dumas and L Patrick Gage. View Institutional Ownership Trends for Tetraphase Pharmaceuticals.

Who bought Tetraphase Pharmaceuticals stock? Who is buying Tetraphase Pharmaceuticals stock?

Tetraphase Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Canada Pension Plan Investment Board, Dimensional Fund Advisors LP, Candriam Luxembourg S.C.A., Schwab Charles Investment Management Inc., Bank of New York Mellon Corp, Cubist Systematic Strategies LLC and Brighton Jones LLC. View Insider Buying and Selling for Tetraphase Pharmaceuticals.

How do I buy Tetraphase Pharmaceuticals stock?

Shares of Tetraphase Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Tetraphase Pharmaceuticals' stock price today?

One share of Tetraphase Pharmaceuticals stock can currently be purchased for approximately $6.88.

How big of a company is Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals has a market capitalization of $353.73 million and generates $5.14 million in revenue each year. The biopharmaceutical company earns ($77,480,000.00) in net income (profit) each year or ($2.87) on an earnings per share basis. Tetraphase Pharmaceuticals employs 66 workers across the globe.

How can I contact Tetraphase Pharmaceuticals?

Tetraphase Pharmaceuticals' mailing address is 480 Arsenal St Ste 110, WATERTOWN, MA 02472-2891, United States. The biopharmaceutical company can be reached via phone at +1-617-7153600 or via email at [email protected]


MarketBeat Community Rating for Tetraphase Pharmaceuticals (NASDAQ TTPH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  220 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  399
MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $17.00 (147.09% upside)

Consensus Price Target History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Price Target History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Analysts' Ratings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/6/2017HC WainwrightBoost Price TargetBuy$15.00 -> $17.00N/AView Rating Details
10/4/2017BMO Capital MarketsBoost Price TargetOutperform$13.00 -> $24.00N/AView Rating Details
9/17/2017Needham & Company LLCReiterated RatingHoldHighView Rating Details
9/12/2017Stifel NicolausReiterated RatingBuy$13.00LowView Rating Details
8/28/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$14.00HighView Rating Details
11/4/2016WedbushReiterated RatingNeutral$4.00N/AView Rating Details
5/16/2016GabelliReiterated RatingNeutralN/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Earnings by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Earnings History by Quarter for Tetraphase Pharmaceuticals (NASDAQ TTPH)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.63)($0.63)$1.59 million$4.10 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.76)($0.83)$1.54 million$1.59 millionViewN/AView Earnings Details
5/2/2017Q1 2017($0.60)($0.79)$1.46 million$1.48 millionViewN/AView Earnings Details
3/8/2017Q4($0.60)($0.61)$1.28 million$1.09 millionViewListenView Earnings Details
11/3/2016($0.50)($0.58)$1.58 million$0.90 millionViewN/AView Earnings Details
8/4/2016Q2($0.46)($0.47)$2.05 million$1.20 millionViewN/AView Earnings Details
5/4/2016Q1($0.44)($0.46)$2.20 million$2.00 millionViewN/AView Earnings Details
2/23/2016Q4($0.44)($0.50)$3.23 million$2.47 millionViewListenView Earnings Details
11/2/2015Q315($0.65)($0.49)$3.20 million$2.90 millionViewN/AView Earnings Details
8/5/2015Q215($0.62)($0.72)$2.73 million$3.30 millionViewN/AView Earnings Details
5/6/2015Q115($0.64)($0.66)$2.90 million$3.00 millionViewN/AView Earnings Details
3/5/2015($0.54)($0.69)$2.74 million$3.07 millionViewN/AView Earnings Details
11/10/2014Q314($0.56)($0.55)$2.86 million$2.29 millionViewN/AView Earnings Details
8/12/2014Q214($0.54)($0.71)$2.79 million$1.30 millionViewN/AView Earnings Details
5/12/2014Q114($0.45)($0.53)$2.97 million$2.50 millionViewN/AView Earnings Details
3/6/2014($0.46)($0.49)ViewN/AView Earnings Details
11/11/2013Q3($0.39)($0.49)$2.43 million$2.20 millionViewN/AView Earnings Details
5/13/2013Q113($0.27)($0.30)$2.49 million$2.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
2017 EPS Consensus Estimate: ($2.48)
2018 EPS Consensus Estimate: ($2.41)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.62)($0.56)($0.59)
Q2 20172($0.63)($0.58)($0.61)
Q3 20172($0.76)($0.59)($0.68)
Q4 20172($0.69)($0.53)($0.61)
Q1 20181($0.61)($0.61)($0.61)
Q2 20181($0.62)($0.62)($0.62)
Q3 20181($0.60)($0.60)($0.60)
Q4 20181($0.58)($0.58)($0.58)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Tetraphase Pharmaceuticals (NASDAQ TTPH)

Insider Ownership Percentage: 5.50%
Institutional Ownership Percentage: 47.40%
Insider Trades by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Institutional Ownership by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Insider Trades by Quarter for Tetraphase Pharmaceuticals (NASDAQ TTPH)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/31/2017Jacques DumasInsiderSell8,750$6.03$52,762.50View SEC Filing  
8/22/2017Jacques DumasInsiderSell17,500$6.00$105,000.00View SEC Filing  
8/17/2017Jacques DumasInsiderSell7,155$5.86$41,928.30View SEC Filing  
3/15/2017L Patrick GageDirectorBuy11,000$7.49$82,390.00View SEC Filing  
9/1/2015Guy MacdonaldinsiderSell10,000$41.57$415,700.00View SEC Filing  
8/14/2015David Charles LubnerCFOSell9,500$42.92$407,740.00View SEC Filing  
8/13/2015Patrick Taylor HornInsiderSell10,000$44.69$446,900.00View SEC Filing  
8/12/2015L Patrick GageDirectorSell15,000$45.00$675,000.00View SEC Filing  
7/20/2015Guy MacdonaldInsiderSell15,000$50.72$760,800.00View SEC Filing  
7/14/2015David Charles LubnerCFOSell7,500$48.92$366,900.00View SEC Filing  
7/13/2015Patrick Taylor HornInsiderSell10,000$48.93$489,300.00View SEC Filing  
7/6/2015John Craig ThompsonCOOSell10,000$47.91$479,100.00View SEC Filing  
7/1/2015Guy MacdonaldInsiderSell10,000$47.92$479,200.00View SEC Filing  
6/15/2015David Charles LubnerCFOSell17,500$41.45$725,375.00View SEC Filing  
6/15/2015John Craig ThompsonCOOSell10,000$41.51$415,100.00View SEC Filing  
6/8/2015John Craig ThompsonCOOSell22,499$43.26$973,306.74View SEC Filing  
6/1/2015Guy MacdonaldInsiderSell16,087$41.89$673,884.43View SEC Filing  
5/11/2015Guy MacdonaldInsiderSell20,000$41.51$830,200.00View SEC Filing  
1/20/2015Guy MacdonaldInsiderSell34,135$36.59$1,248,999.65View SEC Filing  
10/2/2014John Gordon FreundDirectorSell247,734$20.88$5,172,685.92View SEC Filing  
10/1/2014John Gordon FreundDirectorSell142,146$20.84$2,962,322.64View SEC Filing  
9/30/2014John Gordon FreundDirectorSell152,266$20.18$3,072,727.88View SEC Filing  
9/29/2014John Gordon FreundDirectorSell95,648$20.19$1,931,133.12View SEC Filing  
9/23/2014Guy MacdonaldInsiderSell10,000$18.47$184,700.00View SEC Filing  
9/17/2014Guy MacdonaldInsiderSell10,000$18.00$180,000.00View SEC Filing  
9/17/2014John Gordon FreundDirectorSell144,356$17.21$2,484,366.76View SEC Filing  
9/12/2014John Gordon FreundDirectorSell55,644$17.01$946,504.44View SEC Filing  
9/8/2014John Gordon FreundDirectorSell16,700$15.01$250,667.00View SEC Filing  
9/4/2014John Gordon FreundDirectorSell183,300$15.05$2,758,665.00View SEC Filing  
9/3/2014John Gordon FreundDirectorSell142,100$15.04$2,137,184.00View SEC Filing  
8/20/2014Guy MacdonaldInsiderSell10,000$11.59$115,900.00View SEC Filing  
7/18/2014Guy MacdonaldInsiderSell15,000$10.61$159,150.00View SEC Filing  
6/23/2014John Gordon FreundDirectorSell47,184$13.77$649,723.68View SEC Filing  
6/20/2014John Gordon FreundDirectorSell152,816$13.39$2,046,206.24View SEC Filing  
6/17/2014David Charles LubnerCFOSell13,530$12.51$169,260.30View SEC Filing  
6/17/2014Guy MacdonaldInsiderSell15,000$12.28$184,200.00View SEC Filing  
5/19/2014Guy MacdonaldInsiderSell15,000$9.00$135,000.00View SEC Filing  
5/19/2014Steven Ph.D. GullansDirectorBuy25,000$9.24$231,000.00View SEC Filing  
5/14/2014L Patrick GageDirectorBuy5,000$9.25$46,250.00View SEC Filing  
4/14/2014Guy MacdonaldInsiderSell15,000$9.69$145,350.00View SEC Filing  
3/20/2014Joyce SutcliffeSVPSell11,494$12.41$142,640.54View SEC Filing  
3/6/2014David Charles LubnerCFOSell4,510$13.65$61,561.50View SEC Filing  
2/20/2014Joyce SutcliffeSVPSell11,494$14.00$160,916.00View SEC Filing  
2/12/2014David Charles LubnerCFOSell4,506$13.92$62,723.52View SEC Filing  
2/7/2014David Charles LubnerCFOSell9,928$14.22$141,176.16View SEC Filing  
2/5/2014Joyce SutcliffeSVPSell11,494$13.93$160,111.42View SEC Filing  
9/18/2013Ventures Vi Lp Cmeamajor shareholderSell100,000$10.20$1,020,000.00View SEC Filing  
9/17/2013Ventures Vi Lp Cmeamajor shareholderSell53,468$9.26$495,113.68View SEC Filing  
3/25/2013John Gordon FreundDirectorBuy681,012$7.00$4,767,084.00View SEC Filing  
3/25/2013Medical Fund Lp ExcelMajor ShareholderBuy496,121$7.00$3,472,847.00View SEC Filing  
3/20/2013Fmr LlcInsiderBuy642,857$7.00$4,499,999.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Tetraphase Pharmaceuticals (NASDAQ TTPH)

Source:
DateHeadline
Tetraphase Pharmaceuticals, Inc. (TTPH) Expected to Announce Quarterly Sales of $2.26 MillionTetraphase Pharmaceuticals, Inc. (TTPH) Expected to Announce Quarterly Sales of $2.26 Million
www.americanbankingnews.com - November 9 at 1:06 PM
ETFs with exposure to Tetraphase Pharmaceuticals, Inc. : November 6, 2017ETFs with exposure to Tetraphase Pharmaceuticals, Inc. : November 6, 2017
finance.yahoo.com - November 7 at 12:35 PM
Tetraphase Pharmaceuticals, Inc. (TTPH) Expected to Post Earnings of -$0.61 Per ShareTetraphase Pharmaceuticals, Inc. (TTPH) Expected to Post Earnings of -$0.61 Per Share
www.americanbankingnews.com - November 7 at 5:28 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Price Target Increased to $17.00 by Analysts at HC WainwrightTetraphase Pharmaceuticals, Inc. (TTPH) Price Target Increased to $17.00 by Analysts at HC Wainwright
www.americanbankingnews.com - November 6 at 9:58 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) to Post FY2017 Earnings of ($2.93) Per Share, SunTrust Banks ForecastsTetraphase Pharmaceuticals, Inc. (TTPH) to Post FY2017 Earnings of ($2.93) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - November 6 at 2:10 AM
Tetraphase Pharmaceuticals, Inc. :TTPH-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Tetraphase Pharmaceuticals, Inc. :TTPH-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 5 at 7:42 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Cut to Sell at Zacks Investment ResearchTetraphase Pharmaceuticals, Inc. (TTPH) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - November 4 at 8:22 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Given Average Recommendation of "Hold" by BrokeragesTetraphase Pharmaceuticals, Inc. (TTPH) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 4 at 1:40 AM
Tetraphase Pharmaceuticals Inc (TTPH) Insider Sells $52,762.50 in StockTetraphase Pharmaceuticals Inc (TTPH) Insider Sells $52,762.50 in Stock
www.americanbankingnews.com - November 2 at 8:54 PM
Tetraphase Pharmaceuticals Inc (TTPH) Posts  Earnings ResultsTetraphase Pharmaceuticals Inc (TTPH) Posts Earnings Results
www.americanbankingnews.com - November 2 at 7:32 PM
Tetraphase Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Clinical and Corporate AchievementsTetraphase Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Clinical and Corporate Achievements
finance.yahoo.com - November 2 at 10:13 AM
Tetraphase reports 3Q lossTetraphase reports 3Q loss
finance.yahoo.com - November 2 at 10:13 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Upgraded to Hold at Zacks Investment ResearchTetraphase Pharmaceuticals, Inc. (TTPH) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - October 28 at 9:06 AM
RSI Alert: Tetraphase Pharmaceuticals (TTPH) Now OversoldRSI Alert: Tetraphase Pharmaceuticals (TTPH) Now Oversold
www.thestreet.com - October 27 at 7:09 AM
Head to Head Review: Tetraphase Pharmaceuticals (TTPH) and Aceto Corporation (ACET)Head to Head Review: Tetraphase Pharmaceuticals (TTPH) and Aceto Corporation (ACET)
www.americanbankingnews.com - October 25 at 3:44 PM
Analyzing Tetraphase Pharmaceuticals (TTPH) & Its RivalsAnalyzing Tetraphase Pharmaceuticals (TTPH) & Its Rivals
www.americanbankingnews.com - October 25 at 3:42 PM
Tetraphase Pharmaceuticals, Inc. (TTPH) Set to Announce Earnings on WednesdayTetraphase Pharmaceuticals, Inc. (TTPH) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 25 at 3:48 AM
Generic Drugs Stocks on Investors Radar -- pSivida, Tetraphase Pharma, Catalent, and Lannett - PR Newswire (press release)Generic Drugs Stocks on Investors' Radar -- pSivida, Tetraphase Pharma, Catalent, and Lannett - PR Newswire (press release)
www.prnewswire.com - October 19 at 10:06 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Expected to Announce Earnings of -$0.63 Per ShareTetraphase Pharmaceuticals, Inc. (TTPH) Expected to Announce Earnings of -$0.63 Per Share
www.americanbankingnews.com - October 18 at 2:22 PM
Generic Drugs Stocks on Investors Radar -- pSivida, Tetraphase Pharma, Catalent, and LannettGeneric Drugs Stocks on Investors' Radar -- pSivida, Tetraphase Pharma, Catalent, and Lannett
www.bizjournals.com - October 18 at 9:49 AM
Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : TTPH-US : October 18, 2017Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : TTPH-US : October 18, 2017
finance.yahoo.com - October 18 at 9:49 AM
Tetraphase Pharma (TTPH) Appoints Kam Unninayar as CFOTetraphase Pharma (TTPH) Appoints Kam Unninayar as CFO
www.streetinsider.com - October 17 at 8:25 AM
Tetraphase Pharmaceuticals Appoints Kam Unninayar as Chief Financial OfficerTetraphase Pharmaceuticals Appoints Kam Unninayar as Chief Financial Officer
finance.yahoo.com - October 17 at 8:25 AM
Analyzing Adamis Pharmaceuticals Corporation (ADMP) and Tetraphase Pharmaceuticals (TTPH)Analyzing Adamis Pharmaceuticals Corporation (ADMP) and Tetraphase Pharmaceuticals (TTPH)
www.americanbankingnews.com - October 15 at 8:28 PM
Tetraphase Pharmaceuticals, Inc. (TTPH) Receives Average Recommendation of "Hold" from BrokeragesTetraphase Pharmaceuticals, Inc. (TTPH) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 10 at 2:32 AM
FY2017 EPS Estimates for Tetraphase Pharmaceuticals, Inc. Decreased by Analyst (TTPH)FY2017 EPS Estimates for Tetraphase Pharmaceuticals, Inc. Decreased by Analyst (TTPH)
www.americanbankingnews.com - October 9 at 2:56 AM
Equities Analysts Set Expectations for Tetraphase Pharmaceuticals, Inc.s Q3 2017 Earnings (TTPH)Equities Analysts Set Expectations for Tetraphase Pharmaceuticals, Inc.'s Q3 2017 Earnings (TTPH)
www.americanbankingnews.com - October 9 at 1:02 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Rating Lowered to Hold at Zacks Investment ResearchTetraphase Pharmaceuticals, Inc. (TTPH) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 7 at 11:54 PM
Tetraphase Pharma (TTPH) Announced Clinical Data from Oral Eravacycline Development ProgramTetraphase Pharma (TTPH) Announced Clinical Data from Oral Eravacycline Development Program
www.streetinsider.com - October 6 at 11:54 AM
BMO Capital Markets Boosts Tetraphase Pharmaceuticals, Inc. (TTPH) Price Target to $24.00BMO Capital Markets Boosts Tetraphase Pharmaceuticals, Inc. (TTPH) Price Target to $24.00
www.americanbankingnews.com - October 4 at 10:32 PM
Tetraphase Pharma (TTPH) Announced Clinical Data from Oral Eravacycline Development Program - StreetInsider.comTetraphase Pharma (TTPH) Announced Clinical Data from Oral Eravacycline Development Program - StreetInsider.com
www.streetinsider.com - October 4 at 9:27 AM
Tetraphase Pharmaceuticals Presents Clinical Data from Oral Eravacycline Development Program at IDWeek 2017Tetraphase Pharmaceuticals Presents Clinical Data from Oral Eravacycline Development Program at IDWeek 2017
finance.yahoo.com - October 4 at 9:27 AM
Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : TTPH-US : September 25, 2017Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : TTPH-US : September 25, 2017
finance.yahoo.com - October 3 at 2:00 PM
Tetraphase Pharmaceuticals to Present Data at IDWeek 2017Tetraphase Pharmaceuticals to Present Data at IDWeek 2017
finance.yahoo.com - October 3 at 2:00 PM
Tetraphase Pharmaceuticals, Inc. – Value Analysis (NASDAQ:TTPH) : September 26, 2017Tetraphase Pharmaceuticals, Inc. – Value Analysis (NASDAQ:TTPH) : September 26, 2017
finance.yahoo.com - October 3 at 2:00 PM
 Analysts Anticipate Tetraphase Pharmaceuticals, Inc. (TTPH) Will Post Quarterly Sales of $1.46 Million Analysts Anticipate Tetraphase Pharmaceuticals, Inc. (TTPH) Will Post Quarterly Sales of $1.46 Million
www.americanbankingnews.com - October 1 at 3:38 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Expected to Post Earnings of -$0.56 Per ShareTetraphase Pharmaceuticals, Inc. (TTPH) Expected to Post Earnings of -$0.56 Per Share
www.americanbankingnews.com - September 29 at 8:20 PM
Short Interest in Tetraphase Pharmaceuticals, Inc. (TTPH) Declines By 32.0%Short Interest in Tetraphase Pharmaceuticals, Inc. (TTPH) Declines By 32.0%
www.americanbankingnews.com - September 29 at 1:30 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Stock Rating Reaffirmed by Needham & Company LLCTetraphase Pharmaceuticals, Inc. (TTPH) Stock Rating Reaffirmed by Needham & Company LLC
www.americanbankingnews.com - September 17 at 8:58 AM
Tetraphase Pharmaceuticals: Funding Completed, On To The Next Catalyst - Seeking AlphaTetraphase Pharmaceuticals: Funding Completed, On To The Next Catalyst - Seeking Alpha
seekingalpha.com - September 17 at 8:51 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Short Interest UpdateTetraphase Pharmaceuticals, Inc. (TTPH) Short Interest Update
www.americanbankingnews.com - September 16 at 1:20 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Receives Consensus Recommendation of "Hold" from AnalystsTetraphase Pharmaceuticals, Inc. (TTPH) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - September 15 at 2:32 AM
Tetraphase Pharmaceuticals (TTPH) "Buy" Rating Reiterated at Stifel NicolausTetraphase Pharmaceuticals' (TTPH) "Buy" Rating Reiterated at Stifel Nicolaus
www.americanbankingnews.com - September 12 at 11:23 AM
$1.46 Million in Sales Expected for Tetraphase Pharmaceuticals, Inc. (TTPH) This Quarter$1.46 Million in Sales Expected for Tetraphase Pharmaceuticals, Inc. (TTPH) This Quarter
www.americanbankingnews.com - September 12 at 1:36 AM
Tetraphase Pharmaceuticals Completes Enrollment of IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract InfectionsTetraphase Pharmaceuticals Completes Enrollment of IGNITE3 Phase 3 Clinical Trial of Eravacycline in Complicated Urinary Tract Infections
finance.yahoo.com - September 11 at 7:59 AM
Tetraphase Pharmaceuticals Inc (TTPH) Expected to Announce Earnings of -$0.56 Per ShareTetraphase Pharmaceuticals Inc (TTPH) Expected to Announce Earnings of -$0.56 Per Share
www.americanbankingnews.com - September 11 at 12:08 AM
Tetraphase Pharmaceuticals to Present at Upcoming Investor ConferencesTetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
finance.yahoo.com - September 5 at 9:32 AM
ETFs with exposure to Tetraphase Pharmaceuticals, Inc. : September 1, 2017ETFs with exposure to Tetraphase Pharmaceuticals, Inc. : September 1, 2017
finance.yahoo.com - September 1 at 10:08 AM
Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : TTPH-US : August 31, 2017Tetraphase Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : TTPH-US : August 31, 2017
finance.yahoo.com - August 31 at 11:20 AM
Tetraphase Pharmaceuticals, Inc. (TTPH) Coverage Initiated at Piper Jaffray CompaniesTetraphase Pharmaceuticals, Inc. (TTPH) Coverage Initiated at Piper Jaffray Companies
www.americanbankingnews.com - August 28 at 11:20 AM

Social Media

Financials

Chart

Tetraphase Pharmaceuticals (NASDAQ TTPH) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.